WilmerHale Counsels Catabasis in $42M Public Offering

WilmerHale Counsels Catabasis in $42M Public Offering

Firm News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the closing of a $42 million underwritten public offering of common stock and warrant units on June 22, 2018. Oppenheimer & Co. Inc. is acting as the sole underwriter for the offering. Catabasis intends to use the net proceeds for the planned Phase 3 clinical trial of edasalonexent for the treatment of Duchenne muscular dystrophy, as well as for working capital and other corporate purposes.

The WilmerHale team representing Catabasis is led by Rosemary Reilly and includes Jeffries Oliver-Li and Libby Ragan.

Read Catabasis’ press release about the offering. 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel